The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio

Journal of Rheumatology

Volumn 36, Issue 1, 2009, Pages 120-126

  Rauner, Martina ^a,b,e   Stupphann, Daniela ^a   Haas, Martin ^a   Fert, Ingrid ^c   Glatigny, Simon ^c   Sipos, Wolfgang ^d   Breban, Maxime ^c   Pietschmann, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Hôpital Cochin ^*  (France)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Bone rankl; HLA B27 transgenic rat; Spondyloarthropathy osteoporosis

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; HLA B27 ANTIGEN; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROCOLLAGEN; PROPEPTIDE OF TYPE 1 PROCOLLAGEN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE TISSUE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; GENE EXPRESSION; LUMBAR SPINE; MALE; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOID; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RNA ISOLATION; SPONDYLOARTHRITIS; SPONDYLOARTHROPATHY; TIBIA; TRABECULAR BONE; TRANSGENIC RAT;

ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HLA-B27 ANTIGEN; HUMANS; MALE; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; RATS; RATS, INBRED F344; RATS, TRANSGENIC; RNA, MESSENGER; SPONDYLARTHRITIS;

EID: 58149526655     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080475     Document Type: Article

References (24)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90.
2. Breban M, Hacquard-Bouder C, Falgarone G. Animal models of HLA-B27-associated diseases. Curr Mol Med 2004;4:31-40.
3. Breban M. Genetics of spondyloarthritis. Best Pract Res Clin Rheumatol 2006;20:593-9.
4. Hacquard-Bouder C, Ittah M, Breban M. Animal models of HLAB27-associated diseases: new outcomes. Joint Bone Spine 2006;73:132-8.
5. May NY, Tatakis DN. Accelerated alveolar bone loss in male HLA-B27 transgenic rats: adult onset. J Periodont Res 2004;39:33-6.
6. Akhter MP, Jung LK. Decreased bone strength in HLA-B27 transgenic rat model of spondyloarthropathy. Rheumatology Oxford 2007;46:1258-62.
7. Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol 2007;143:31-48.
8. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004;4:268-75.
9. Stupphann D, Rauner M, Krenbek D, et al. Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int 2008;28:987-93.
10. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
11. Grisar J, Bernecker PM, Aringer M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6.
12. Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factors-kappa B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis. Rheumatology Oxford 2006;45:1197-200.
13. Borman P, Bodur H, Bingol N, Bingol S, Bostan EE. Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease activity. J Clin Rheumatol 2001;7:315-21.
14. Speden DJ, Calin AI, Ring FJ, Bhalla AK. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 2002;29:516-21.
15. El Maghraoui A, Tellal S, Chaouir S, et al. Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis. Clin Rheumatol 2005;24:346-51.
16. Yilmaz N, Ozaslan J. Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 2000;19:92-8.
17. Hacquard-Bouder C, Falgarone G, Bosquet A, et al. Defective costimulatory function is a striking feature of antigen-presenting cells in an HLA-B27-transgenic rat model of spondylarthropathy. Arthritis Rheum 2004;50:1624-35.
18. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099-112.
19. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
20. Rissanen JP, Suominen MI, Peng Z, et al. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int 2008;82:155-61.
21. Zhang Y, Shi S, Ciurli C, Poole AR. Animal models of ankylosing spondylitis. Curr Rheumatol Rep 2002;4:507-12.
22. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290-8.
23. Tran TM, Dorris ML, Satumtira N, et al. Additional human beta 2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006;54:1317-27.
24. Hacquard-Bouder C, Chimenti MS, Giquel B, et al. Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27. Arthritis Rheum 2007;56:1478-89.